keyword
https://read.qxmd.com/read/38635030/health-related-quality-of-life-following-salvage-radical-prostatectomy-for-recurrent-prostate-cancer-after-radiotherapy-or-focal-therapy
#1
JOURNAL ARTICLE
Severin Rodler, Dina Danninger, Lennert Eismann, Philipp Maximilian Kazmierczak, Friedrich Jokisch, Minglun Li, Armin Becker, Alexander Kretschmer, Christian Stief, Thilo Westhofen
BACKGROUND: Salvage radical prostatectomy (sRP) is an important treatment option for patients with recurrent prostate cancer (PCa) after radiotherapy (RT) or focal therapy (FT). However, health-related quality of life (HRQOL) after sRP depending on the primary treatment is understudied. METHODS: Patients who underwent Salvage RP for recurrent PCa were analyzed. The primary outcome of this study was HRQOL assessed by the quality-of-life questionnaire (QLQ)-C30 and its prostate specific QLQ-PR25 add-on...
April 18, 2024: World Journal of Urology
https://read.qxmd.com/read/38633832/patient-centred-pathology-reporting-improves-patient-experience-and-understanding-of-disease-in-prostate-cancer-care
#2
JOURNAL ARTICLE
Haidar Al Saffar, Alice Thomson, Jo-Lynn S Tan, Qiwei Wang, Emma Birch, Samantha Koschel, Elizabeth Medhurst, Dale Jobson, Sean Ong, Daniel A Moon, Declan Murphy, Nathan Lawrentschuk
INTRODUCTION AND OBJECTIVES: Patient-centred (PC) and holistic care improves patient satisfaction and health outcomes. We sought to investigate the benefit of utilising a PC pathology report in patients undergoing radical prostatectomy (RP) for prostate cancer (PCa). Our study aimed to evaluate and compare patient understanding of their PCa diagnosis after RP, upon receiving either a standard histopathology report or a personalised and PC report (PCR). Moreover, we evaluated knowledge retention at 4 weeks after the initial consultation...
April 2024: BJUI compass
https://read.qxmd.com/read/38633827/the-potential-role-of-precision-medicine-to-alleviate-racial-disparities-in-prostate-bladder-and-renal-urological-cancer-care
#3
REVIEW
Kunal K Sindhu, Zachary Dovey, Marcher Thompson, Anthony D Nehlsen, Karin A Skalina, Beata Malachowska, Shaakir Hasan, Chandan Guha, Justin Tang, Lucas Resende Salgado
BACKGROUND: Racial disparities in oncological outcomes resulting from differences in social determinants of health (SDOH) and tumour biology are well described in prostate cancer (PCa) but similar inequities exist in bladder (BCa) and renal cancers (RCCs). Precision medicine (PM) aims to provide personalized treatment based on individual patient characteristics and has the potential to reduce these inequities in GU cancers. OBJECTIVE: This article aims to review the current evidence outlining racial disparities in GU cancers and explore studies demonstrating improved oncological outcomes when PM is applied to racially diverse patient populations...
April 2024: BJUI compass
https://read.qxmd.com/read/38633512/a-case-report-of-hereditary-leiomyomatosis-and-renal-cell-carcinoma-hlrcc
#4
Sunao Nohara, Shotaro Nakanishi, Tomoki Matsuo, Tomoko Tamaki, Seiici Saito
Leiomyomatosis and renal cell carcinoma (HLRCC) are rare autosomal dominant cancer syndromes characterized by cutaneous leiomyoma, uterine leiomyoma, and renal cell carcinoma (RCC). RCC in HLRCC is an aggressive metastatic tumor that develops at a young age. Here, we report the case of a patient with HLRCC who was diagnosed after the spontaneous rupture of a renal tumor. The patient underwent cytoreductive surgery, followed by combination therapy with the immune checkpoint inhibitor (ICI) nivolumab and cabozantinib, a tyrosine kinase inhibitor (TKI); however, no improvements were achieved...
May 2024: Urology Case Reports
https://read.qxmd.com/read/38632863/stepwise-algorithm-using-computed-tomography-and-magnetic-resonance-imaging-for-differential-diagnosis-of-fat-poor-angiomyolipoma-in-small-renal-masses-a-prospective-validation-study
#5
JOURNAL ARTICLE
Masahiro Toide, Hajime Tanaka, Masaki Kobayashi, Motohiro Fujiwara, Yuki Nakamura, Shohei Fukuda, Koichiro Kimura, Yuma Waseda, Soichiro Yoshida, Ukihide Tateishi, Yasuhisa Fujii
OBJECTIVES: To validate the diagnostic accuracy of a stepwise algorithm to differentiate fat-poor angiomyolipoma (fp-AML) from renal cancer in small renal masses (SRMs). METHODS: We prospectively enrolled 223 patients with solid renal masses <4 cm and no visible fat on unenhanced computed tomography (CT). Patients were assessed using an algorithm that utilized the dynamic CT and MRI findings in a stepwise manner. The diagnostic accuracy of the algorithm was evaluated in patients whose histology was confirmed through surgery or biopsy...
April 17, 2024: International Journal of Urology: Official Journal of the Japanese Urological Association
https://read.qxmd.com/read/38632212/impact-of-health-and-digital-health-literacy-on-quality-of-life-following-radical-prostatectomy-for-prostate-cancer-prospective-single-center-cohort-study
#6
JOURNAL ARTICLE
Ahmet Keles, Muhammed Kose, Umit Furkan Somun, Meftun Culpan, Nese Yaksi, Asıf Yıldırım
PURPOSE: The importance of health literacy (HL) and digital health literacy (e-HL) in promoting healthy behavior and informed decision making is becoming increasingly apparent. This study aimed to assess the effects of HL and e-HL on the quality of life (QoL) of men who underwent radical prostatectomy (RP) for localized prostate cancer. MATERIALS AND METHODS: This prospective observational study included 104 patients who underwent RP for localized prostate cancer...
April 17, 2024: World Journal of Urology
https://read.qxmd.com/read/38631994/re-stereotactic-ablative-body-radiotherapy-for-primary-kidney-cancer-trog-15-03-fastrack-ii-a-non-randomised-phase-2-trial
#7
JOURNAL ARTICLE
Aimin Jiang, Ying Liu, Chen Cai, Peng Luo, Linhui Wang
No abstract text is available yet for this article.
April 16, 2024: European Urology
https://read.qxmd.com/read/38631993/re-enfortumab-vedotin-and-pembrolizumab-in-untreated-advanced-urothelial-cancer
#8
JOURNAL ARTICLE
David C Chen, Haidar AlSaffar, Henrike Graefen, Sachin Perera, Elio Mazzone, Marlon L Perera, Nathan Lawrentschuk, Declan G Murphy
No abstract text is available yet for this article.
April 16, 2024: European Urology
https://read.qxmd.com/read/38631992/a-systematic-review-on-the-impact-of-quality-assurance-programs-on-outcomes-after-radical-prostatectomy
#9
REVIEW
Sophia H van der Graaf, Marinus J Hagens, Hans Veerman, Ton A Roeleveld, Jakko A Nieuwenhuijzen, Esther M K Wit, Michel W J M Wouters, Stevie van der Mierden, R Jeroen A van Moorselaar, Harrie P Beerlage, André N Vis, Pim J van Leeuwen, Henk G van der Poel
BACKGROUND AND OBJECTIVE: The implementation of quality assurance programs (QAPs) within urological practice has gained prominence; yet, their impact on outcomes after radical prostatectomy (RP) remains uncertain. This paper aims to systematically review the current literature regarding the implementation of QAPs and their impact on outcomes after robot-assisted RP, laparoscopic RP, and open prostatectomy, collectively referred to as RP. METHODS: A systematic Embase, Medline (OvidSP), and Scopus search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process, on January 12, 2024...
April 16, 2024: European Urology Focus
https://read.qxmd.com/read/38631991/biomarkers-of-response-to-anti-nectin4-antibody-drug-conjugate-enfortumab-vedotin-in-urothelial-cancer
#10
REVIEW
Niklas Klümper, Markus Eckstein
Initial studies indicated that NECTIN4 expression is widespread in metastatic urothelial cancer (mUC), which led to approval of the anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) for unselected patients with mUC. However, the recent literature suggests that there has been overestimation of membranous NECTIN4 expression in UC, which is a prerequisite for EV binding. It is well established from the development of Her2-targeting ADCs that treatment response is strongly dependent on membranous expression level of the relevant target antigen...
April 16, 2024: European Urology Focus
https://read.qxmd.com/read/38631967/open-versus-minimally-invasive-nephroureterectomy-in-octogenarians-an-analysis-of-surgical-approach-trends-outcomes-and-survival-analysis-with-propensity-matching
#11
JOURNAL ARTICLE
Shaun Trecarten, Mukund Bhandari, Ahmad Abdelaziz, Onika Noel, Michael Liss, Furkan Dursun, Robert Svatek, Ahmed M Mansour
INTRODUCTION: Upper tract urothelial carcinoma (UTUC) is a rare disease accounting only for 5%-10% of urothelial carcinoma (UC). For localized high-risk disease, radical nephroureterectomy (RNU) is the standard of care. While minimally invasive (MIS) RNU has not been shown to decisively improve overall survival (OS) compared to open surgery, MIS RNU has been associated with reduced hospital length of stay (LOS), blood transfusion requirements and improved recovery, which are important considerations when treating older patients...
April 16, 2024: Urologic Oncology
https://read.qxmd.com/read/38630912/preclinical-models-for-bladder-cancer-therapy-research
#12
JOURNAL ARTICLE
Iris Ertl, Shahrokh F Shariat, Walter Berger, Bernard Englinger
PURPOSE OF REVIEW: Bladder cancer (BC) is a highly heterogenous disease comprising tumours of various molecular subtypes and histologic variants. This heterogeneity represents a major challenge for the development of novel therapeutics. Preclinical models that closely mimic in vivo tumours and reflect their diverse biology are indispensable for the identification of therapies with specific activity in various BC subtypes. In this review, we summarize efforts and progress made in this context during the last 24 months...
April 17, 2024: Current Opinion in Urology
https://read.qxmd.com/read/38627553/unlocking-ferroptosis-in-prostate-cancer-the-road-to-novel-therapies-and-imaging-markers
#13
REVIEW
Pham Hong Anh Cao, Abishai Dominic, Fabiola Ester Lujan, Sanjanaa Senthilkumar, Pratip K Bhattacharya, Daniel E Frigo, Elavarasan Subramani
Ferroptosis is a distinct form of regulated cell death that is predominantly driven by the build-up of intracellular iron and lipid peroxides. Ferroptosis suppression is widely accepted to contribute to the pathogenesis of several tumours including prostate cancer. Results from some studies reported that prostate cancer cells can be highly susceptible to ferroptosis inducers, providing potential for an interesting new avenue of therapeutic intervention for advanced prostate cancer. In this Perspective, we describe novel molecular underpinnings and metabolic drivers of ferroptosis, analyse the functions and mechanisms of ferroptosis in tumours, and highlight prostate cancer-specific susceptibilities to ferroptosis by connecting ferroptosis pathways to the distinctive metabolic reprogramming of prostate cancer cells...
April 16, 2024: Nature Reviews. Urology
https://read.qxmd.com/read/38627150/european-association-of-urology-european-society-for-paediatric-urology-guidelines-on-paediatric-urology-summary-of-the-2024-updates
#14
REVIEW
Michele Gnech, Allon van Uitert, Uchenna Kennedy, Martin Skott, Alexandra Zachou, Berk Burgu, Marco Castagnetti, Lisette't Hoen, Fardod O'Kelly, Josine Quaedackers, Yazan F Rawashdeh, Mesrur Selcuk Silay, Guy Bogaert, Christian Radmayr
BACKGROUND AND OBJECTIVE: We present an overview of the 2024 updates for the European Association of Urology (EAU)/European Society for Paediatric Urology (ESPU) guidelines on paediatric urology to offer evidence-based standards for perioperative management, minimally invasive surgery (MIS), hydrocele, congenital lower urinary tract obstruction (CLUTO), trauma/emergencies, and fertility preservation. METHODS: A broad literature search was performed for each condition...
April 15, 2024: European Urology
https://read.qxmd.com/read/38627107/estimation-of-the-incidence-of-urachal-cancer-a-systematic-review-and-meta-analysis-of-registry-based-studies
#15
JOURNAL ARTICLE
Csilla Olah, András Kubik, Péter Mátrai, Marie Anne Engh, Viktória Barna, Péter Hegyi, Henning Reis, Péter Nyirády, Tibor Szarvas
BACKGROUND: Urachal cancer (UrC) is a rare disease with limited availability of representative incidence and clinical data. Although, the prevalence is accounting for less than 1% of bladder tumors, the 5-year survival rate is around only 50% for patients with resectable tumors, and even worse for patients with metastatic disease. Due to the lack of comprehensive prospective studies, our current knowledge of UrC is still limited. OBJECTIVE: The present study aimed to summarize the available registry-based studies with unselected UrC patients to evaluate its incidence and clinicopathological characteristics...
April 15, 2024: Urologic Oncology
https://read.qxmd.com/read/38627106/use-of-inpatient-palliative-care-in-metastatic-urethral-cancer
#16
JOURNAL ARTICLE
Carolin Siech, Andrea Baudo, Mario de Angelis, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A Goyal, Zhe Tian, Fred Saad, Shahrokh F Shariat, Nicola Longo, Luca Carmignani, Ottavio de Cobelli, Alberto Briganti, Séverine Banek, Philipp Mandel, Luis A Kluth, Felix K H Chun, Pierre I Karakiewicz
BACKGROUND: In metastatic urethral cancer, temporal trends, and patterns of inpatient palliative care (IPC) use are unknown. METHODS: Relying on the National Inpatient Sample (2006-2019), metastatic urethral cancer patients were stratified according to IPC use. Estimated annual percentage changes (EAPC) analyses and multivariable logistic regression models (LRM) for the prediction of IPC use were fitted. RESULTS: Of 1,106 metastatic urethral cancer patients, 199 (18%) received IPC...
April 15, 2024: Urologic Oncology
https://read.qxmd.com/read/38627025/adjuvant-intravesical-therapy-in-intermediate-risk-non-muscle-invasive-bladder-cancer
#17
JOURNAL ARTICLE
Ekaterina Laukhtina, Paolo Gontero, Marko Babjuk, Marco Moschini, Jeremy Yuen-Chun Teoh, Morgan Rouprêt, Quoc-Dien Trinh, Piotr Chlosta, Péter Nyirády, Mohammad Abufaraj, Francesco Soria, Jakob Klemm, Kensuke Bekku, Akihiro Matsukawa, Shahrokh F Shariat
OBJECTIVE: To evaluate the impact of adjuvant therapy on oncological outcomes in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC), as due to the poorly-defined and overlapping diagnostic criteria optimal decision-making remains challenging in these patients. PATIENTS AND METHODS: In this multicentre study, patients treated with transurethral resection of bladder tumour for Ta disease were retrospectively analysed. All patients with low- or high-risk NMIBC were excluded from the analysis...
April 16, 2024: BJU International
https://read.qxmd.com/read/38626735/primary-results-of-patients-with-genitourinary-malignancies-presented-at-a-molecular-tumor-board
#18
JOURNAL ARTICLE
Jakob Michaelis, Ruth Himmelsbach, Patrick Metzger, Silke Lassmann, Melanie Börries, Martin Werner, Cornelius Miething, Rouven Höfflin, Anna L Illert, Justus Duyster, Heiko Becker, August Sigle, Christian Gratzke, Markus Grabbert
PURPOSE: Personalized medicine poses great opportunities and challenges. While therapeutic landscape markedly expands, descriptions about status, clinical implementation and real-world benefits of precision oncology and molecular tumor boards (MTB) remain sparse, particularly in the field of genitourinary (GU) cancer. Hence, this study characterized urological MTB cases to better understand the potential role of MTB in uro-oncology. METHODS: We analyzed patients with complete data sets being reviewed at an MTB from January 2019 to October 2022, focusing on results of molecular analysis and treatment recommendations...
April 16, 2024: Urologia Internationalis
https://read.qxmd.com/read/38625439/early-experience-and-future-prospects-regarding-use-of-newly-developed-surgical-robot-system-hinotori-in-the-field-of-urologic-cancer-surgery
#19
REVIEW
Hideaki Miyake, Masato Fujisawa
In the field of urology, robotic surgery has gained rapid and wide acceptance as a standard surgical approach in the majority of major surgeries over the last decade. To date, the da Vinci surgical system has been the dominant platform in robotic surgery; however, several newly developed robotic systems have recently been introduced in routine clinical practice. Of these, hinotori, the first made-in-Japan robotic system, is characterized by various unique and attractive features different from the existing system, and the use of this system has gradually increased mainly in urologic cancer surgeries, including radical prostatectomy, partial nephrectomy, radical nephrectomy, and radical nephroureterectomy...
April 16, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38625417/global-burden-of-bladder-cancer-mortality-in-2020-and-2040-according-to-globocan-estimates
#20
JOURNAL ARTICLE
András Wéber, Jerome Vignat, Richa Shah, Eileen Morgan, Mathieu Laversanne, Péter Nagy, István Kenessey, Ariana Znaor
INTRODUCTION: In 2020, bladder cancer (BC) was the seventh most prevalent cancer in the world, with 5-year prevalence of more than 1.7 million cases. Due to the main risk factors-smoking and chemical exposures-associated with BC, it is considered a largely preventable and avoidable cancer. An overview of BC mortality can allow an insight not only into the prevalence of global risk factors, but also into the varying efficiency of healthcare systems worldwide. For this purpose, this study analyzes the national mortality estimates for 2020 and projected future trends up to 2040...
April 16, 2024: World Journal of Urology
keyword
keyword
170686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.